Citius Pharmaceuticals, Inc. CTXR
Set alert
At close · Oct 30
After hours · Oct 30, 6:56 PM ET
- YTD
- -32.68%
- 1 year
- -66.68%
- Open
- 0.564
- Prev close
- 0.5631
- Mkt cap
- 14.36M
- Vol
- 104.67K
- Avg vol
- 474.58K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5207
- High
- 0.564
- Forward P/E
- 15.32
- Beta
- 1.66
- Short ratio
- 1.23
- Inst. own
- 13.17%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 3, 2025
- 50-d avg
- 6.51
- 200-d avg
- 14.50
- 1y target
- 54.00
News
6 days ago gurufocus.com
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIRÂ Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2
-
6 days ago benzinga.com
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
itius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius
6 days ago prnewswire.com
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of…
2 weeks ago prnewswire.com
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference CRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius…
3 weeks ago defenseworld.net
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Wall Street Brokerages
Shares of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) have been given a consensus recommendation of "Hold" by the five brokerages that are presently covering the company,…
1 month ago defenseworld.net
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
1 month ago defenseworld.net
Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) has been given a consensus recommendation of "Hold" by the five research firms that are currently covering the company, MarketBeat…
1 month ago prnewswire.com
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth &…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release,…
-
2 months ago benzinga.com
Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 57.5 percent increase over losses of $(0.80)…
2 months ago prnewswire.com
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions…
2 months ago prnewswire.com
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and…
2 months ago prnewswire.com
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius…
-
2 months ago benzinga.com
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal payer coverage expands market accessInitial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR…
2 months ago prnewswire.com
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…
-
3 months ago benzinga.com
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by AugustCRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")…
3 months ago prnewswire.com
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")…
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
5 months ago benzinga.com
Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR),…
5 months ago prnewswire.com
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily…
5 months ago prnewswire.com
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
5 months ago prnewswire.com
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no…
5 months ago prnewswire.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5…
6 months ago prnewswire.com
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets…
6 months ago prnewswire.com
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
6 months ago benzinga.com
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after the company announced a registered direct offering, a financing move that often pressures micro-cap biotech stocks due to dilution…
6 months ago benzinga.com
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
6 months ago prnewswire.com
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
Gold Edges Lower; Omeros Shares Jump
Gold Edges Lower; Omeros Shares Jump
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 months ago benzinga.com
Dow Gains Over 100 Points; US Jobless Claims Decline
Dow Gains Over 100 Points; US Jobless Claims Decline
10 months ago benzinga.com
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs and headline were updated in the story.) U.S. stock futures slipped on Wednesday after Tuesday’s higher close. Futures of major benchmark…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 months ago benzinga.com
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can Fite Biopharma announces reverse split.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
1 year ago benzinga.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session